India’s Healthcare & Pharma Sectors: 10-15% Growth by FY27

India’s healthcare and pharmaceutical sectors are poised for substantial expansion, with projections indicating a 10-15% growth rate by fiscal year 2027. This anticipated surge moves beyond traditional volume-based strategies, focusing instead on technological integration and specialized medical care.

The shift is underpinned by several enabling factors within the Indian market. Improved digital infrastructure, alongside a notable increase in insurance penetration, is facilitating advanced medical treatments and broader access.

Key Growth Projections

• Hospital sector: Expected to grow by 10% to 15% in FY27.
• Pharmaceutical sector: Anticipates 5% to 15% growth for FY27.
• Manufacturing capacity: 55% of pharma leaders plan 10% to 30% increase in next three years.

The hospital segment, in particular, is capitalizing on private equity investments and internal capital. These funds are directed towards infrastructure development and specialized facilities, including robotic surgery and organ transplant units.

Hospitals are also integrating modern enterprise systems to ensure digital connectivity with government health platforms. Significant potential for expansion exists outside major urban centers, considering the current hospital bed density stands at 1.6 per 1,000 people.

Strategic Shifts in Pharma

The pharmaceutical sector’s growth is driven by a strategic pivot towards higher-value products. This includes biologics, biosimilars, and new chemical entities, designed to exploit global opportunities like the upcoming patent cliff.

Healthcare funding in India has also seen positive changes, with out-of-pocket expenditure decreasing from over 60% in FY15 to below 40% recently. This reduction is primarily attributed to expanding insurance coverage across the population.

Despite this positive outlook, the sectors face challenges. Companies must navigate high capital expenditure demands for new facilities and intense competition across both domestic and export markets. Investors will need to closely monitor debt management strategies and ensure that demand for specialty treatments genuinely aligns with aggressive investment plans.